FDA
-
-
-
-
-
-
-
Scienture reports 449% revenue growth in first quarter 2026
-
-
-
-
-
-
-
SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
-
-
-
-
-
-
-
Scienture expands naloxone spray access through GPO deals
-
-
-
-
-
-
-
SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
-
-
-
-
-
-
-
SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
-
-
-
-
-
-
-
Scienture Holdings Announces Cancelation of ELOC
-
-
-
-
-
-
-
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days
-
323,584 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

